These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26253304)

  • 1. Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness.
    van Hees F; Saini SD; Lansdorp-Vogelaar I; Vijan S; Meester RG; de Koning HJ; Zauber AG; van Ballegooijen M
    Gastroenterology; 2015 Nov; 149(6):1425-37. PubMed ID: 26253304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study.
    Ladabaum U; Mannalithara A; Mitani A; Desai M
    Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):318-328. PubMed ID: 31796524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline.
    Meester RGS; Peterse EFP; Knudsen AB; de Weerdt AC; Chen JC; Lietz AP; Dwyer A; Ahnen DJ; Siegel RL; Smith RA; Zauber AG; Lansdorp-Vogelaar I
    Cancer; 2018 Jul; 124(14):2974-2985. PubMed ID: 29846942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis.
    van Hees F; Habbema JD; Meester RG; Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG
    Ann Intern Med; 2014 Jun; 160(11):750-9. PubMed ID: 24887616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations.
    Dinh TA; Alperin P; Walter LC; Smith R
    J Gen Intern Med; 2012 Jun; 27(6):730-8. PubMed ID: 22237663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
    Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
    Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population.
    Javadinasab H; Daroudi R; Salimzadeh H; Delavari A; Vezvaie P; Malekzadeh R
    Arch Iran Med; 2017 Sep; 20(9):564-571. PubMed ID: 29048918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis.
    Meester RGS; Lansdorp-Vogelaar I; Winawer SJ; Zauber AG; Knudsen AB; Ladabaum U
    Ann Intern Med; 2019 Nov; 171(9):612-622. PubMed ID: 31546257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
    van den Puttelaar R; Nascimento de Lima P; Knudsen AB; Rutter CM; Kuntz KM; de Jonge L; Escudero FA; Lieberman D; Zauber AG; Hahn AI; Inadomi JM; Lansdorp-Vogelaar I
    Gastroenterology; 2024 Jul; 167(2):368-377. PubMed ID: 38552671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of a cost-effective blood test for colorectal cancer screening.
    Nascimento de Lima P; van den Puttelaar R; Knudsen AB; Hahn AI; Kuntz KM; Ozik J; Collier N; Alarid-Escudero F; Zauber AG; Inadomi JM; Lansdorp-Vogelaar I; Rutter CM
    J Natl Cancer Inst; 2024 Oct; 116(10):1612-1620. PubMed ID: 38845072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
    Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
    Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 17. Should colorectal cancer screening start at different ages for men and women? Cost-effectiveness analysis for a resource-constrained service.
    Thomas C; Mandrik O; Whyte S; Saunders CL; Griffin SJ; Usher-Smith JA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1344. PubMed ID: 33533190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualizing colonoscopy screening by sex and race.
    Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG; Boer R; Wilschut J; Winawer SJ; Habbema JD
    Gastrointest Endosc; 2009 Jul; 70(1):96-108, 108.e1-24. PubMed ID: 19467539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
    Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study.
    van Hees F; Zauber AG; Klabunde CN; Goede SL; Lansdorp-Vogelaar I; van Ballegooijen M
    JAMA Intern Med; 2014 Oct; 174(10):1568-76. PubMed ID: 25133641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.